Tessera

Folgen

Myllia Biotechnology

@mylliabio.bsky.social

Primary cell CRISPR screens to accelerate drug discovery and target selection at single-cell resolution

56 Posts29 Follower 18 Folgt

Myllia Biotechnology @mylliabio.bsky.social · 2w ago

Teamwork makes the dreamwork! Every individual at Myllia plays an important role in advancing science and helping CROP-Seq data reach companies working on target discovery. Today, we’re proud to highlight the employees that are part of #TeamMyllia 🔗 myllia.com/about-us/

Myllia Biotechnology @mylliabio.bsky.social · 3w ago

Following the success of “Perturb 2026: High-Content CRISPR Screening”, we’re proud to announce the second edition of the conference to take place from 17th to 18th of March 2027. This time, we’re heading Stateside to one of the busiest cities on the planet: New York City! 🔗 www.perturb2027.bio

Myllia Biotechnology @mylliabio.bsky.social · 4w ago

People of #TeamMyllia Our most recent group picture features almost everyone in the team, reflecting how international, multifaceted and diverse our company has become. Learn more about us: myllia.com/about-us/

Myllia Biotechnology @mylliabio.bsky.social · last mo.

Optical pooled screens combine genetic perturbations with microscopy-based phenotypic readouts. In this data spotlight, Myllia’s CRISPR screening technology was combined with Element Biosciences’ AVITI24™ instrument to identify regulators of NF-κB signalling in a HeLa cell line. (1/5)

Myllia Biotechnology @mylliabio.bsky.social · 2mo ago

We’re live at the Single-Cell & Spatial Day in Basel! Sumit has just presented our VISTA technology platform, highlighting how we can perform single-cell CRISPR screening in primary human macrophages and dendritic cells to enable unbiased drug target discovery.

Sumit presenting Mylia's primary human cells applications

Myllia Biotechnology @mylliabio.bsky.social · 2mo ago

Myllia is heading to the 4th Basel Single Cell & Spatial Day! 🚀 Meet Anke and Sumit at our booth to discuss CRISPR screens for drug target discovery. Don’t miss Sumit’s 10:10 talk on single-cell CRISPR screens in primary human cells. More info: myllia.com/events/4th-s...

Myllia Biotechnology @mylliabio.bsky.social · 2mo ago

Stefanie is heading to Berlin to represent Myllia at Discovery & Development Europe 2026 She will present a poster on how pooled CRISPR screenings were combined with InTraSeq, a single-cell method that measures RNA alongside intracellular and surface proteins. 🔗 shorturl.at/2XihX @cellsignal.com

Myllia Biotechnology @mylliabio.bsky.social · 2mo ago

Join us on June 16th at 2PM CET for a hybrid seminar with Element Biosciences! Molly He, Matthew Gow, and Tillmann Burckstümmer will discuss single-cell multiomics, NGS, and how optical pooled CRISPR screening identified NF-κB regulators in human cells Learn more and register: shorturl.at/6VQkD

Myllia Biotechnology @mylliabio.bsky.social · 2mo ago

We’re heading to #BIO2026! Connect with Myllia as we share how our high-content CRISPR screening technology can fuel drug target discovery. Stay tuned for more details on where to find us and what we’ll be showcasing. Book a meeting with us: convention.bio.org/partner

Myllia Biotechnology @mylliabio.bsky.social · 2mo ago

Two weeks to our Element Biosciences webinar! Tillmann Burckstummer and Jens Durruthy Durruthy will take the stage to discuss how optical pooled CRISPR screens revealed NF-kB regulators in human cells. 📅 June 10th 🕑09:00 PDT/ 12:00 EDT/ 16:00 GMT 🔗https://shorturl.at/3DGEf

Myllia Biotechnology @mylliabio.bsky.social · 3mo ago

Myllia is attending SLAS Europe in Vienna! May 19th - Henrik, our VP Commercial, will present Myllia's high-content CRISPR screening platform. May 20th - Tilmann, CSO, will showcase how our VISTA platform deciphers primary human macrophage biology. 🔗https://shorturl.at/PEbuc

Myllia Biotechnology @mylliabio.bsky.social · 3mo ago

Meet Myllia Biotechnology at #CIMT2026 in Mainz 🇩🇪 Our Assoc. Director of R&D, Sumit, will present on pooled CRISPR screening for drug target discovery in primary human macrophages—highlighting our VISTA platform. 📅 May 11–13 👉 myllia.com/events/cimt-...

Myllia Biotechnology @mylliabio.bsky.social · 6mo ago

🚀 Are you ready to push the boundaries of bio AI foundation models? @mylliabio.bsky.social is thrilled to host "Echoes of Silenced Genes" - A Global Community Prediction Competition! 🔗 Learn more here and join the competition: myllia.com/events/commu... #AI #BioAI #CRISPR #Perturb2026

Myllia's Perturbation Prediction Challenge 2026: Echoes of Silenced Genes - Can you predict how CRISPRi perturbations influence the phenotypes of human cells?

Functional Genomics Center Zurich @fgcz-en.bsky.social · 6mo ago

Kick off 2026 with a deep dive into single-cell science! 🚀 Join FGCZ & BD Biosciences on March 9 in Zurich for the BD Rhapsody™ Science Days. Featuring: 🔬 Dr. Simone Picelli (IOB, Basel) 🧬 @mylliabio.bsky.social 🩺 Dr. Marc Beyer (DZNE, Bonn) ✨ Dr. Luciano Martelotto (BD) 🔗 tinyurl.com/wbffw5an

Myllia Biotechnology @mylliabio.bsky.social · 8mo ago

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18–19, 2026, in Vienna, Austria. The early-bird registration is open via the conference website: www.perturb2026.bio Meet the Speaker: Sami Farhi

Dr. Sami Farhi leads the Spatial Technology Platform at the Broad Institute of MIT and Harvard. The platform’s goal is to bring next-generation spatial transcriptomics and proteomics approaches to bear on large-scale biological problems. In his parallel research lab, Sami focuses on continuing technology development and iPS-based screens for understanding psychiatric disease with optical methods. Sami joined the Broad Institute in July 2018 after completing his Ph.D. in chemical biology at Harvard University. He also holds a B.S. in chemical biology from the University of California, Berkeley.

Myllia Biotechnology @mylliabio.bsky.social · 8mo ago

Are you interested in single-cell genomics, AI-ready perturbation data and virtual cell models? The registration for the "High-Content CRISPR Screening" conference in March 2026 is open via the website: perturb2026.bio Meet the Speaker: Ci Chu

Dr. Ci Chu is the Senior Vice President of AI-Enabled Discovery at Xaira Therapeutics, where he leads the team building the massive biological data generation engine fueling Xaira's generative AI models. With over a decade of experience working at the intersection of discovery biology and AI/ML, he has previously led high-impact functional genomics and multi-modal phenotyping teams at insitro, Verily and Google X.

Myllia Biotechnology @mylliabio.bsky.social · 8mo ago

We’re excited to announce the expansion of Myllia’s commercial team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. At @mylliabio.bsky.social, we’ve built a unique, scalable CRISPR screening platform!

We’re excited to announce the expansion of Myllia’s global commercial leadership team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. Their expertise strengthens our ability to support partners worldwide as we advance next-generation CRISPR screening technologies!

At Myllia Biotechnology, we’ve built a unique, scalable CRISPR screening platform:

- Unbiased drug target discovery powered by high-throughput, pooled CRISPR screening
- Primary human cell models that translate in vivo, e.g., T helper cells and myeloid cells
- Single-cell resolution for deeply resolved functional genomics

Get in touch via info@myllia.com and come join the “High-Content CRISPR Screening” conference in March 2026:

www.perturb2026.bio

#TeamMyllia #CRISPR #FunctionalGenomics #DrugDiscovery

Myllia Biotechnology @mylliabio.bsky.social · 8mo ago

Are you interested in single-cell genomics and drug target discovery? The "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria. Conference website: perturb2026.bio Meet the Speaker: @thijnbrummel.bsky.social

Dr. Thijn Brummelkamp is Director of Research at the Netherlands Cancer Institute with a research interest in the fields of cell biology and cancer biology. Thijn uses genetics in human cells to identify genes important for human disease. During his Ph.D. studies, Thijn developed a system for expressing shRNA molecules, which allowed for long-term gene inhibition. He used this to carry out the first RNA interference-based screen in human cells, revealing the function of the CYLD tumor suppressor gene. His lab also developed haploid human cells as a genetic model system, using this approach to discover host factors for pathogens, such as the cholesterol transporter NPC1 as the long-sought entry receptor for the Ebola virus. More recently, he has applied haploid genetics to uncover missing enzymes and alternative cellular pathways, leading to the discovery of the elusive enzyme crucial for mature actin production, an alternative triglyceride synthesis pathway, and a pathway that explains DNA damage-induced cancer cell death in the absence of p53.

Myllia Biotechnology @mylliabio.bsky.social · 9mo ago

Are you interested in single-cell genomics and CRISPR applications? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Website: www.perturb2026.bio Meet the Speaker: @johanneszuber.bsky.social

Dr. Johannes Zuber is a Senior Group Leader at the Research Institute of Molecular Pathology (IMP) and an Adjunct Professor at the Medical University in Vienna. His lab develops and applies inducible loss-of-function genetic tools (iCas9, Tet-shRNAmir, ARTi, AID2), time-resolved transcriptomics, FACS-based and in-vivo screens to characterize regulatory pathways and dependencies in cancer and tumor-associated immune cells. He has been awarded with the German Cancer Prize in 2016 and elected as an EMBO member in 2022.

Myllia Biotechnology @mylliabio.bsky.social · 9mo ago

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. The registration and abstract submission is now open via the conference website: perturb2026.bio Meet the Speaker: @priscaliberali.bsky.social

Dr. Prisca Liberali is Full Professor at ETH Zurich (D-BSSE) and Senior Group Leader at the Friedrich Miescher Institute for Biomedical Research (FMI) in Basel. Her laboratory combines high-content imaging, CRISPR-based perturbations, and computational modeling to uncover how single-cell variability drives tissue self-organization and regeneration. By developing quantitative pipelines that integrate genome editing with multiscale microscopy, her group maps genetic interactions and mechanochemical pathways controlling organoid morphogenesis. Liberali’s work bridges molecular systems biology, developmental dynamics, and quantitative imaging, providing mechanistic insights into how collective behaviors emerge from single-cell decisions.

Myllia Biotechnology @mylliabio.bsky.social · 9mo ago

Are you interested in single-cell genomics and AI/ML models? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Conference website: perturb2026.bio Meet the Speaker: @yusufroohani.bsky.social

Dr. Yusuf Roohani is a Machine Learning Group Leader at the Arc Institute. His research explores how artificial intelligence can guide experimental design in biological discovery, with a particular focus on predictive models of cell state. Recently, he helped design the Virtual Cell Challenge, an initiative to measure progress toward predicting cell behavior under perturbation. Yusuf earned his Ph.D. at Stanford University, where he was advised by Jure Leskovec and Stephen Quake. Prior to that, he spent four years at GSK as a Machine Learning Engineer working on early-stage drug discovery.

Myllia Biotechnology @mylliabio.bsky.social · 9mo ago

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract! Conference website: perturb2026.bio Meet the Speaker: @leopoldparts.bsky.social

Dr. Leopold Parts initially trained in mathematics and computer science before switching to molecular biology and genomics for his Ph.D., and high-throughput screening for the postdoctoral research. He is currently a group leader at the Wellcome Sanger Institute, where his team aims to understand human DNA function in its cellular context. To do so, they currently focus on generating data from cell lines whose genomes carry many large-scale systematic changes compared to the reference. His team has created several tools and datasets to probe the editing efficacies of CRISPR/Cas systems, as well as applied them to map the extent of variation in gene phenotypes between individuals.

Myllia Biotechnology @mylliabio.bsky.social · 9mo ago

Myllia Biotechnology @mylliabio.bsky.social · 10mo ago

Next week, @mylliabio.bsky.social is heading to the Biotech Summit Austria 2025! Join us in Graz and meet with Thomas Moser and Anke Loregger-Wiesmann to explore CRISPR-based functional genomics!

Myllia Biotechnology @mylliabio.bsky.social · 10mo ago

Dr. Xin Jin is an HHMI Freeman Hrabowski Scholar, Associate Professor of Neuroscience at Scripps Research, a member of the Dorris Neuroscience Center, and Adjunct Professor of Cognitive Science at UC San Diego. She received her BSc in Chemistry from MIT and her PhD in Biology from The Rockefeller University working in the Lab of Cori Bargmann. As a Junior Fellow at the Harvard Society of Fellows, she worked with Paola Arlotta, Feng Zhang and Aviv Regev to develop and apply in vivo genetic screening technologies to study brain development and homeostasis. She is the recipient of the Pew Biomedical Scholar, McKnight Scholar Award, Early Career Investigator Award from the International Society of Autism Research and was named as one of the ‘35 Innovators Under 35’ by MIT Tech Review.

Myllia Biotechnology @mylliabio.bsky.social · 10mo ago

Myllia Biotechnology is heading to @elrig.org Drug Discovery 2025! Meet with Lukas Badertscher, Stefanie Fellinger, and Henrik Schmidt to explore CRISPR-based functional genomics for drug target discovery. Spotlight Talk, Day 1, 12.40 PM Posters #3, #45, and #107 Booth D02

Myllia Biotechnology @mylliabio.bsky.social · 10mo ago

Don’t forget to register and submit an abstract for the 'High-Content CRISPR Screening' conference, which will take place in Vienna, Austria, on 18–19 March 2026! Conference website: www.perturb2026.bio Meet the Speaker: Silvia Domcke

Dr. Silvia Domcke’s research group at the University of Zurich combines single cell genomics and large-scale CRISPR screens to predict de novo transcription factor activity in mammalian cells and engineer cell state transitions. Previously, Silvia led a computational team at a San Francisco biotech startup, applying in vivo Perturb-Seq for target discovery in complex diseases. A biochemist by training, she became enamored with comparative genomics and perturbation approaches at Memorial Sloan-Kettering Cancer Center in New York, built a foundation in gene regulatory mechanisms during her PhD at the Friedrich Miescher Institute in Basel and expanded this expertise to high-throughput single cell methods during her postdoc at the University of Washington in Seattle.

Myllia Biotechnology @mylliabio.bsky.social · 10mo ago

Are you interested in single-cell genomics, multi-modal perturbation data and drug target discovery? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria! Meet the Speaker: Radu Rapiteanu www.perturb2026.bio

Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.

Myllia Biotechnology @mylliabio.bsky.social · 10mo ago

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. The registration is now open via the conference website: perturb2026.bio Meet the Speaker: Mathew Garnett @mgarnett.bsky.social

Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.

Myllia Biotechnology @mylliabio.bsky.social · 11mo ago

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria. The registration is now open via the website: perturb2026.bio Meet the Speaker: Jake P. Taylor-King

Prior to co-founding Relation Therapeutics, Dr. Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access.